APA

Malard F., Labopin M., Yakoub-Agha I., Chantepie S., Guillaume T., Blaise D., Tabrizi R., Magro L., Vanhove B., Blancho G., Moreau P., Gaugler B., Chevallier P. & Mohty M. (20171128). Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study. : Blood.

Chicago

Malard Florent, Labopin Myriam, Yakoub-Agha Ibrahim, Chantepie Sylvain, Guillaume Thierry, Blaise Didier, Tabrizi Reza, Magro Leonardo, Vanhove Bernard, Blancho Gilles, Moreau Philippe, Gaugler Béatrice, Chevallier Patrice and Mohty Mohamad. 20171128. Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study. : Blood.

Harvard

Malard F., Labopin M., Yakoub-Agha I., Chantepie S., Guillaume T., Blaise D., Tabrizi R., Magro L., Vanhove B., Blancho G., Moreau P., Gaugler B., Chevallier P. and Mohty M. (20171128). Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study. : Blood.

MLA

Malard Florent, Labopin Myriam, Yakoub-Agha Ibrahim, Chantepie Sylvain, Guillaume Thierry, Blaise Didier, Tabrizi Reza, Magro Leonardo, Vanhove Bernard, Blancho Gilles, Moreau Philippe, Gaugler Béatrice, Chevallier Patrice and Mohty Mohamad. Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study. : Blood. 20171128.